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HumanEssential hypertension affects 20 to 30% of the population worldwide and contributes signiﬁcantly to
cardiovascular mortality and morbidity. Heridability of blood pressure is around 15 to 40% but there are also
substantial environmental factors affecting blood pressure variability. It is assumed that blood pressure is
under the control of a large number of genes each of which has only relatively mild effects. It has therefore
been difﬁcult to discover the genes that contribute to blood pressure variation using traditional approaches
including candidate gene studies and linkage studies. Animal models of hypertension, particularly in the rat,
have led to the discovery of quantitative trait loci harbouring one or several hypertension related genes, but
translation of these ﬁndings into human essential hypertension remains challenging. Recent development of
genotyping technology made large scale genome-wide association studies possible. This approach and the
study of monogenic forms of hypertension has led to the discovery of novel and robust candidate genes for
human essential hypertension, many of which require functional analysis in experimental models.tudy; QTL, Quantitative trait
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sm; WTCCC, Wellcome Trust
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Hypertension is characterised by chronic elevation of blood
pressure and affects 20 to 30% of the population worldwide [1].
Hypertension contributes signiﬁcantly to the global burden of
cardiovascular morbidity and mortality. A recent study by Lawes
et al. [2] concluded that 13.5% of premature deaths and 54% of stroke
and 47% of ischaemic heart disease worldwide are attributable to high
blood pressure. Alarmingly, about 80% of the attributable burden
occurred in low-income and middle-income economies, and over half
occurred in people aged 45 to 69 years. Blood pressure is a continuous,
quantitative trait whereas the dichotomous deﬁnition of hypertension
(i.e. blood pressure above a certain threshold) is to some degree
arbitrary and has been modiﬁed with expanding knowledge over the
years. This has been acknowledged by recent guidelines where
borderline or pre-hypertension states have been introduced and
recommendations for blood pressure cut-offs and targets are
dependent on comorbidities such as diabetes or renal disease [3,4].
Blood pressure in the upper range of normal is also associated with
increased cardiovascular morbidity and mortality. Only half of theburden in the study by Lawes et al. [2] was in people with
hypertension, whereas the remainder was in subjects with lesser
degrees of high blood pressure (≥115 mmHg but <140 mmHg
systolic). It appears that there is a continuous relationship between
blood pressure and cardiovascular risk without evidence of a
threshold down to at least 115/75 mm Hg [5].
These considerations have major implications on studies into the
genetics of hypertension. A qualitative trait of “hypertension” could be
subject to classic Mendelian laws of inheritance whereas a continuous
“blood pressure” trait would constitute a non-Mendelian complex
trait [6]. The normal unimodal distribution of blood pressure in the
general population supports the latter [7]. However, there are rare
monogenic Mendelian forms of hypertension which demonstrate that
at least some forms of hypertension and possibly even some
components of blood pressure could be explained by classic
Mendelian inheritance [6]. From family and twin studies heritabilities
of systolic and diastolic blood pressure are generally estimated in the
range of 15 to 40% and 15 to 30%, respectively [8–10]. The sibling
recurrent risk of hypertension is in the range of 1.2 to 1.5 [11].
However, these ﬁgures are inﬂuenced by non genetic factors including
shared environment and measurement errors so that the magnitude
of the genetic effect could be different.
Another fundamental problem in the genetics of hypertension is
the deﬁnition of the ancestral phenotype. Hypertension is a disease of
modern civilisation and heavily depends on environmental and
particularly dietary factors of modern society. For example, members
of the Luo tribe had lower blood pressure in their traditional rural
environment than in the urban environment of Nairobi where their
urinary sodium concentration was higher and urinary potassium
concentration was lower [12]. It has been hypothesised that in a
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conserving one. Likewise, the renin–angiotensin–aldosterone system
may have initially been adapted for sodium conservation butmay play
an important role in the pathogenesis of hypertension in modern
societies with high dietary salt intake [13]. These considerations
highlight that for genes associated with hypertension the disease
allele does not necessarily have to be the minor (rare) allele but could
be themajor (for examples sodium conserving) allele as well, and that
studies into genes associated with low blood pressure could be
equally important for the genetics of hypertension.
Our attempts to unravel the genetic basis of human essential
hypertension are complicated by the above considerations and other
challenges we will refer to later. We have previously reviewed this
topic [14] and concluded that a multifaceted approach including and
integrating human and animal studies is a most promising approach.
Ten years later we take the opportunity to update our previous
review. There has been major progress in some areas, mainly driven
by the advances in technology and statistics, but it is fair to say that we
are still not much closer to a complete understanding of the genetics
of hypertension than a decade ago.
2. The rat as a physiological model of hypertension
One strategy to overcome the limitations of functional genetic
studies in humans is to take advantage of speciﬁc hypertensive
rat strains that have been selectively bred over many generations
and are inherently simpler paradigms, but remain under complex
control [15,16]. This is especially relevant, as recent developments
in genome sequencing [17] and software development [18,19] have
accelerated conserved genome analysis and translational studies
between rat and human. Numerous genome-wide studies in rat
models have revealed candidate quantitative trait locus (QTL)
regions on almost every rat chromosome, as well as some important
interactions between loci [15,20]. As with humans, however, the
critical rate-determining step is no longer the identiﬁcation of QTLs,
but the identiﬁcation of the genetic determinant underlying the
QTL.
2.1. Quantitative trait loci inﬂuencing blood pressure
The principal strategy in the rat for the search of genes involved in
the development of hypertension has been the identiﬁcation of QTLs
responsible for blood pressure regulation by genome-wide scanning
[15,21]. The difﬁculties in identifying QTLs include epistasis, and a
limited statistical power due to the number of hypotheses being
tested. Moreover, any single QTL is responsible for only a fraction of
the phenotypic variation and thus the phenotype–genotype correla-
tion is low. Improvements in genomic resources and statistical
analysis have led to the identiﬁcation of a large number of QTLs.
However, despite the numerous complex traits that have been
analysed by genome-wide linkage studies, few of the underlying
genes have been identiﬁed [22].
QTLmapping is a phenotype driven approach that does not require
prior knowledge of either causative genes or their function and can
lead to the identiﬁcation of novel genes involved in disease.
Furthermore, in animal models there is also the distinct advantage
of the construction of congenic strains to ﬁrst verify the existence of
the QTL, and also to allow production of congenic substrains to enable
genetic dissection and ﬁne-mapping in order to reduce QTL intervals
(Fig. 1). This congenic strategy was considered ideal, since initial
estimates suggested the involvement of a relatively few major effect
genes, thus requiring the construction of essentially Mendelian-like
strains to facilitate gene identiﬁcation. However, recent congenic
studies have demonstrated the underlying genetic complexity of large
QTL regions identiﬁed in genome-wide scans. Comprehensive con-
genic coverage on various rat chromosomes has revealed multipleQTLs, with evidence for loci with opposing effects on blood pressure
[23–28]. While congenic ﬁne-mapping can restrict the number of
genes in a QTL interval to a minimum to facilitate gene identiﬁcation
[29], frequent loss of the hypertensive phenotype suggests the
existence of multiple genes. Furthermore, potential epistatic interac-
tions (i.e. the masking of a gene by the effect of another unrelated
gene) may underlie many QTL peaks and congenic intervals [30,31],
and this has hampered progress towards the identiﬁcation of
causative genetic elements.
3. Identifying genetic determinants
Combining congenic ﬁne-mapping, comparative genomic tools,
gene expression array resources, transgenic rescue and knockout
technology in the rat provides a powerful tool for the discovery of
novel genes underlying complex cardiovascular traits. The ﬁrst
successful example of this combined strategy was the identiﬁcation
of the gene encoding Cd36 as a major contributor to insulin resistance
and dyslipidaemia in the spontaneously hypertensive rat (SHR) [32],
conﬁrmed by transgenic rescue [33] and subsequent translation to
human populations [34,35]. However, there was an issue concerning
the contribution of Cd36 to hypertension. These issues have only
recently been resolved by implicating Cd36 as a determinant of blood
pressure and risk for hypertension by speciﬁcally identifying deﬁcient
renal expression of Cd36 [36].
Our own research has focused on the stroke-prone spontane-
ously hypertensive rat (SHRSP), where the genetic determination of
hypertension is due to multiple gene–gene and gene–environment
interactions. Although exceptionally high blood pressure is clearly a
factor for end-organ damage in the SHRSP, genetic factors are also
likely to contribute. In particular, two blood pressure QTLs have
been mapped to rat chromosome 2 [37]. This region of chromosome
2 is a classic example of a common or overlapping QTL because it
has been implicated in several rat crosses. These two QTLs, there-
fore, have become a focus for further congenic strategies in our
laboratory [38] and other laboratories [39]. In combination with
congenic strain construction in the SP.WKYGla2a and SP.WKYGla2c*
strains, genome-wide microarray expression proﬁling identiﬁed
glutathione S-transferase mu type 1 (Gstm1) as a positional
candidate gene for spontaneous hypertension [40–42], and endo-
thelial differentiation gene 1 (Edg1) and vascular cell adhesion
molecule 1 (Vcam1) for salt sensitivity [43].
It is notable that there are still relatively few examples where this
strategy has led to the identiﬁcation of positional and functional
hypertension candidate genes that can be translated and tested in
human populations [44,45]. It is also important to note that narrowing
the QTL interval by substitution mapping remains a critical part of this
combined strategy, as demonstrated recently by the subsequent
elimination of the differentially expressed candidate gene, Resp18,
with the production of the smallest reported rat blood pressure QTL
interval of 117 kb [46]. This highlights that, even with the onset of
extensive genome sequencing, our ability to identify a full comple-
ment of genes and other genetic elements continues to be a challenge.
However, recent evidence suggests that once again, this locus is more
complex than originally believed as further transgenic–congenic rats
conﬁrm the eligibility of Resp18 as a hypertension candidate gene
[47]. This highlights the requirement to modulate the levels of target
genes in the appropriate genetic background with either transgenic
over expression or knockout rats by embryo microinjection of zinc-
ﬁnger nucleases [48].
It should be noted, however, that the efﬁciency of candidate gene
identiﬁcation is very much dependent on the complexity of the
phenotype under investigation. There are many examples of other
disease phenotypes in the rat that have proved more amenable to
candidate gene discovery via congenic strategies including pristane-
induced arthritis [49] and cresentric glomerulonephritis [50,51].
Fig. 1. Selected analytical tools in rat genetics. A) The construction of recombinant inbred animals which are genetic mosaics of the two founding strains, consomic (chromosome
substitution), congenic strains. B) An alternative method for ﬁne-mapping small-effect QTLs uses outbred rats of known ancestry, genetically heterogeneous stock (HS). HS rats are
generated by intercrossing several inbred progenitor strains followed by cross breeding for more than 50 generations.
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As well as advances in genome resources there are a number of
large scale animal resources available for exploitation (Fig. 1).
Consomic rat strains are generated by introgressing an entire
chromosome from one inbred strain into the isogenic background of
another inbred strain using marker-assisted selection. The PhysGen
(http://pga.mcw.edu) Program forGenomicApplication at theMedical
College of Wisconsin developed two panels of consomic rats using theSS/JrHsdMcwi, the FHH/EurMcwi and the BN/NHsdMcwi strains.
Characterization of these consomic strains, each carrying a chromo-
some from the sequenced Brown Norway strain, allows for immediate
mapping of traits to a particular chromosome without the need for
genetic crosses. This is ongoing work, but gene expression [52] and
proteomic [53] analysis has been undertaken in a number of these
consomic strains. From the consomic strains, congenic strains can be
rapidly bred within 6 months to narrow the region on a speciﬁc chro-
mosome to a region that can be targeted for gene identiﬁcation [54].
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to utilise the rat heterogeneous (HS) stock panels. HS rats are
generated by intercrossing several inbred progenitor strains followed
by cross breeding formore than 50 generations. Each chromosome is a
ﬁne-grained mosaic of the progenitor strains: the average distance
between recombinants is small (less than 2cM) so that the HS provide
high resolution mapping of multiple QTLs across the genome. This
allows ﬁne-mapping of QTLs to sub-centimorgan intervals by
exploiting recombinants that have accumulated over many genera-
tions of out breeding in genetically HS that are derived from inbred
strains (Fig. 1). This signiﬁcantly reduces the number of candidate
genes found within each QTL. The best characterised rat heteroge-
neous stock panel was established at the NIH in 1984 and derives from
eight genetically distinct and phenotypically diverse inbred strains
(ACI/N, BN/SsN, BUF/N, F344/N, M520/N, MR/N, WKY/N and WN/
N). Pilot studies in 786 Rat HS [55] strains support the ﬁndings from
the mouse HS [56] indicating reﬁnement of a behaviour QTL
identiﬁcation from 40 cM to 13 Mbp.
One of the great successes in the rat over the past few years has
been the exploitation of the rat recombinant inbred panel (Fig. 1).
A comprehensive genetic screen of the rat recombinant inbred
strains has recently been undertaken in which gene expression
values were considered as expression quantitative traits [57]. This
integration of genome-wide expression proﬁling with linkage
analysis is a new approach to identifying genetic determinants
underlying complex traits. The expression proﬁling of kidney and
fat RNA from all individuals allows the proﬁle of each gene, treated
as an intermediate phenotype, to be considered as an expression
quantitative trait. Furthermore, by conserved genome analysis, a
data set of 73 candidate genes for hypertension, including Cd36
and Gstm1, have been identiﬁed that merit translational studies in
human populations [57]. Other notable successes with this strategy
include candidate genes for heart failure [58] and left ventricular
hypertrophy [59].
5. Translation from animal to man
In our own studies in the SHRSPwe have identiﬁed the glutathione
S-transferase mu type 1 gene (Gstm1) as a positional candidate for
hypertension in the SHRSP [41]. Glutathione S-transferases are
involved in the defences against oxidative stress and thereby also
constitute functional candidates for hypertension [60]. We and others
have conﬁrmed reduced Gstm1 gene [41,57,61] and Gstm1 protein
expression [42] in SHRSP. The human orthologues of Gstm1 are
therefore promising candidate genes for essential hypertension.
However, when we performed a deﬁnite association study of GSTM
genes in hypertension involving sequencing of GSTM genes, genotyp-
ing for the GSTM1 deletion and studies in three different and
independent cohorts, we were unable to show a signiﬁcant associa-
tion between any of the human GSTM genes and hypertension [62].
This apparently negative example illustrates that direct translation
of ﬁndings in experimental animal models to human disease is not
without challenges. To the best of our knowledge there are no
examples of a direct translation of ﬁndings in rodents to man for the
genetics of hypertension. Whilst this may in part be due to differences
in the genetics of hypertension between animals and humans it also
illustrates the general challenges we are facing in candidate gene
studies of human essential hypertension.
6. Candidate gene studies
Candidate genes are chosen for their assumed role in the
pathogenesis of hypertension and can derive from experimental
models or knowledge of the pathophysiology. The most plausible
candidate genes are components of the renin–angiotensin–aldoste-
rone system and genes involved in signal transduction (e.g. the G-protein subunit-β3 gene GNB3), salt and water handling (e.g. the
adducin-α genes ADD1), regulation of vascular tone (e.g. the
endothelial nitric oxide synthase gene NOS3) and production of or
defences against oxidative stress. However, despite numerous reports
on association in small and medium sized cohorts since publication of
our previous review [14] there has been little evidence for a
substantial association of any of these genes or single nucleotide
polymorphisms (SNPs) within these genes with hypertension. The
main reasons for this lack of positive results are (1) the individual
contribution of genetic variants to the blood pressure phenotype is
small; (2) most of the study designs lacked power to detect these
small effects; (3) inconsistency of phenotyping did not allow results
to be compared or combined; (4) selection of candidate genes
depended on known pathways of blood pressure regulation preclud-
ing undiscovered pathways; (5) most of the candidate gene studies
tended to be single SNP studies whichwas not completely informative
of the gene variations and additional SNP identiﬁcation needed
sequencing resourceswhichwere not readily accessible; (6) studies of
rare frequency variants were not done; and (7) the study design
issues mentioned above precluded any meaningful study of gene–
gene or gene–environment interactions. Nevertheless, the candidate
gene approach remains one of the cornerstones of studies into the
genetics of hypertension.We refer to recent reviews on the genetics of
the renin–angiotensin–aldosterone system [63–65], G-proteins [66],
adducin [67], and oxidative stress [68,69] in hypertension, but will
discuss the association of the aldosterone synthase gene (CYP11B2)
with hypertension as an exemplar.
The physiology of aldosterone is relatively well understood. There
is considerable epidemiological evidence that aldosterone has a role in
the development of hypertension and other cardiovascular diseases.
Even within the physiological range, increased plasma aldosterone
levels predispose to development of hypertension [70]. Increased
aldosterone levels in adulthood may be determined by conditions
early in life such as foetal growth [71]. While plasma aldosterone and
aldosterone to renin ratio were found to be heritable phenotypes,
common polymorphisms in the CYP11B2 gene explained only
partially variations in aldosterone levels [72,73]. This is akin to the
previous experience with ACE and AGT levels and like before a large
number of studies have been performed in recent years and these
were meta-analysed by Sookoian et al. [74]. The evidence from the
meta-analysis was borderline for association between hypertension
(qualitative trait) and the C-344T variant of CYP11B2 and no
association seen with systolic and diastolic blood pressure (quanti-
tative trait). In any meta-analysis, the results depend on the
constituent studies, and this is true of most of the studies included
here and all the reasons mentioned above are applicable. Like other
candidate genes, aldosterone synthase is an attractive target, and it is
likely that evidence for association may come from studies of rare or
structural variants in this locus.
With the advances of technology and reduced costs for genotyping
we will see more large scale candidate gene projects in the future. An
example for this approach is the ITMAT/Broad/CARE Vascular Disease
50 k SNP Array (IBC Chip; http://bmic.upenn.edu/cvdsnp/). This chip
allows genotyping of about 50,000 SNPs in 2100 cardiovascular
candidate genes at relatively low costs. Studies into hypertension
have been conducted but reports are still outstanding. The relatively
large scale of these projects necessitates correction for multiple tests
and will therefore have an unfavourable impact on sample size and
power of such studies. Extracting gene speciﬁc data from genome-
wide SNP chips are not very fruitful. A recent example of a study into
160 candidate genes for blood pressure covering 2411 SNPs in 1644
subjects of the KORA S3 cohort is a case in point [75]. None of the SNPs
remained signiﬁcantly associated with blood pressure after Bonfer-
roni correction. The top twelve hits in seven genes for associationwith
blood pressure and/or hypertension (P<10−3) failed to be replicated
in independent cohorts.
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In contrast to candidate gene studies we have seen signiﬁcant
developments in the area of genome-wide linkage and association
studies since publication of our previous review [14]. Historically,
linkage studies were the ﬁrst technically feasible genome-wide
studies of human hypertension. Linkage studies examine transmission
of disease loci from parents to offspring, but modiﬁcations of this
concept allowed studies complex traits in the form of affected sib-pair
studies [76]. The latter is a powerful method of performing linkage
studies with small family sizes, but there are practical issues in
recruitment of families with a mobile adult population worldwide,
although we have recently demonstrated that family-based recruit-
ment is still possible [77].
The British Genetics of Hypertension (BRIGHT) study is probably
the best example for a linkage study into essential hypertension
[11]. The consortium genotyped 2,010 affected sibling pairs drawn
from 1599 severely hypertensive families, and completed a 10cM
genome-wide scan. Linkage analysis identiﬁed a principle locus on
chromosome 6q, with a lod score of 3.21 that attained genome-
wide signiﬁcance (P=0.042). Three further loci with lod scores
higher than 1.57 (2q, 5q, and 9q) also showed genome-wide signi-
ﬁcance (P=0.017) when assessed under a locus-counting analysis.
Genes or functional genetic variants underlying the linkage peaks
have still not been identiﬁed. The authors originally interpreted
these results as evidence for an oligogenic element of human
essential hypertension. However, insufﬁcient marker density and
insufﬁcient sample size to detect genetic variants with small effects
on blood pressure were thought to be limitations of the BRIGHT
study. These limitations have recently been addressed by regeno-
typing hypertensive probands from the BRIGHT study as part of
SNP based genome-wide association studies (GWAS) into common
disease [78].
There have been a number of similar genome-wide linkage
studies. QTLs for blood pressure have been found on virtually all
human chromosomes in linkage studies [79]. Koivukoski et al. [80]
meta-analysed 9 genome-wide scans of blood pressure or hyper-
tension using the genome-search meta-analysis method and found
susceptibility loci on chromosomes 2 (2p12–q22.1) and 3 (3p14.1–
q12.3). Their study demonstrated that sample size is a crucial
factor detection of markers with genome-wide signiﬁcance. Sub-
sequently, we demonstrated a successful attempt at reducing he-
terogeneity by using antihypertensive drug response to partition
different pathways of hypertension [81]. In the BRIGHT population,
hypertensive sib-pairs who were non-responsive to ACE inhibitors,
ARBs or beta-blockers showed signiﬁcant linkage on chromosome
2p (LOD=4.84 at 90.68 Kosambi cM). This susceptibility locus co-
localises to a region found in African-American hypertensives in
the Family Blood Pressure Program who showed evidence of
linkage with hypertension status at 93 cM with a LOD score of 2.84
[82]. Thus the chromosomal 2p locus independently identiﬁed in
different populations may contain a gene or genes for the salt-
sensitive form of hypertension which is common among Africans,
and the same mechanism may be operative in a subset of white
European hypertensives identiﬁed by unresponsiveness to beta-
blockers and ACE inhibitors. Another approach was taken by the
BRIGHT investigators who performed linkage analysis of covariate
data including serum and urine biochemistry, biometric measure-
ments and additional blood pressure phenotypes [83]. Genome-
wide signiﬁcant results were obtained for body mass and renal
function related traits on chromosomes 20 and 5, respectively.
Although these results need to be interpreted with caution as the
analysis has not been adjusted for treatment and was performed in
a selected population of hypertensive subjects, additional pheno-
typic information may help to reduce genetic heterogeneity and
identify novel loci for hypertension.8. Genome-wide association studies
Linkage studies are extremely attractive tools in human genetics
but they can only identify highly penetrant loci and have been notably
successful in the identiﬁcation of monogenic forms of hypertension,
The recent developments in genotyping technology with the
introduction of chip-based genotyping arrays [84,85] has paved the
way for GWAS that genotype for a large number of genetic markers
usually SNPs (for example about 500,000 in the Wellcome Trust Case
Control Consortium (WTCCC) study [78]) as opposed to the highly
polymorphic microsatellite markers that have been used in classic
genome-wide linkage studies. With the resources from Hapmap, it is
possible to impute up to 2.5 million SNPs in LD with the tag SNPs
present in these GWAS SNP arrays.
In 2007 two major GWAS into hypertension have been reported.
Levy et al. [86] conducted a study in Framingham Heart Study families
and associated blood pressures at two different time points and long-
term averaged blood pressure with 100,000 polymorphic markers
using the Affymetrix 100 k chip. In the primary analyses, none of the
associations attained genome-wide signiﬁcance. The other study was
reported by the WTCCC and examined association with 500,000
geneticmarkers in 2000 patients with hypertension (derived from the
BRIGHT cohort) and 3000 control subjects using the Affymetrix 500 k
chip [78]. Also the WTCCC study did not ﬁnd a SNP for hypertension
that achieved genome-wide statistical signiﬁcance. At the same time,
the WTCCC examined other common diseases against the same
common control subjects and successfully identiﬁed loci for coronary
artery disease, bipolar disorder, rheumatoid arthritis, Crohn's disease
and type 1 and 2 diabetes. Whilst the WTCCC study was characterised
by better marker density compared to the Framingham Heart Study,
there have been a number of criticisms about the study design that
may have caused underperformance of hypertension compared to the
other common diseases in the WTCCC study. The common controls
were not selected and in part not even phenotyped for blood pressure.
With a prevalence of hypertension of 20 to 30% in the general
population [1] is very likely that the presence of cases in apparent
controls has reduced the power to identify disease speciﬁc associa-
tions [78]. This concern has been partly addressed by the selection of
cases from the top 5% of blood pressure distribution in the UK
population thereby reducing signiﬁcantly the number of misclassiﬁed
controls with the same phenotype as the cases. Nevertheless, due to
the results of these two GWAS there has been disappointment and
concern that the effect sizes of genes related to hypertension could be
lower than those observed for other common diseases where odds
ratios in the range of 1.2 to 1.5 were found [87]. Most recently a study
in 8842 samples from a Korean general population with replication in
7861 independent samples revealed an association of rs17249754
near the ATP2B1 gene at genome-wide signiﬁcance level [88]. The
effect size of this SNP was relatively small (−1.309±0.266 mmHg for
systolic and−0.882±0.181 mmHg for diastolic blood pressure), but
certainly in a realistic range for a multigenic disorder.
The major breakthrough came with the report of two studies that
examined associations of a large number of SNPs with blood pressure
and hypertension. The Global BPgen consortium tested 2.5 million
genotyped or imputed SNPs for association with systolic or diastolic
blood pressure in 34,433 subjects of European ancestry [89] and
identiﬁed eight regions with genome-wide signiﬁcance. The variants
were near the CYP17A1, CYP1A2, FGF5, SH2B3, MTHFR, ZNF652 and
PLCD3 genes and chromosome 10 open reading frame 107
(c10orf107). These loci were also associated with hypertension as
qualitative trait. The second consortium (CHARGE) studied 2.5 million
genotyped or imputed SNPs in 29,136 subjects and found signiﬁcant
(P<4×10−7) associations with systolic blood pressure for 13 SNPs,
with diastolic blood pressure for 20 SNPs andwith hypertension for 10
SNPs [90]. The data were than meta-analysed with those of the Global
BPGen consortium [89] and revealed genome-wide signiﬁcance
1304 C. Delles et al. / Biochimica et Biophysica Acta 1802 (2010) 1299–1308(P<5×10−8) for ATP2B1 (chromosome 12q21; plasma membrane
calcium ATPase 1), CYP17A1 (chromosome 10q24; steroid 17-alpha-
monooxygenase), PLEKHA7 (chromosome 11p15; pleckstrin homolo-
gy domain containing, family A member 7), SH2B3 (chromosome
12q24; SH2B adaptor protein 3), CACNB2 (chromosome 10p12;
calcium channel, voltage-dependent, beta 2 subunit), CSK-ULK3
(chromosome 15q24; adjacent to c-src tyrosine kinase and unc-51-
like kinase 3 loci), TBX3-TBX5, (chromosome 12q24; adjacent to T-box
transcription factor TBX3 and T-box transcription factor TBX5 loci) and
ULK4 (chromosome 3p22; unc-51-like kinase 4) for association with
systolic or diastolic blood pressure or hypertension.
Despite the impressive samples sizes and even more impressive P-
values it should benoted that the effects of these SNPs onbloodpressure
are rather modest. For example, in Global BPgen the SNP showing the
strongest association with systolic blood pressure (rs11191548,
P=7×10−24) increases systolic blood pressure by 1.16 mmHg per
major allele. Generally an effect of about 1 mmHgper identiﬁed SNP can
be assumed which may have major implications for hypertension
related cardiovascular disease in the population but minor implications
for an individual. Nevertheless, these projects have clearly demonstrat-
ed the existence of blood pressure susceptibility genes with small but
measurable effects. Most of the SNPs are located in genes that have not
immediately been thought to play a major role in the pathogenesis of
hypertension, and it is hoped that these ﬁndings will improve our
understanding of the underlying pathomechanisms.
9. Monogenic forms of hypertension
Since publication of our review in 2000 [14] there has been
considerable progress in the area of rare Mendelian forms of
hypertension. These syndromes account for less than 1% of human
hypertension and because a clear and often treatable reason has been
elucidated, do not immediately explain the genetics of essential
hypertension. However, the Mendelian forms of hypertension are
important because they constitute the archetype of hereditable
hypertension; demonstrate the importance of genes expressed in
the kidney and responsible for salt and water handling in the
pathogenesis of hypertension; and may help to unravel mechanisms
that also apply to the pathogenesis of essential hypertension.
Mendelian forms of hypertension have been reviewed recently
[6,79,91] and are summarised in Table 1. It should be noted that
there are additional syndromes that would go beyond the scope of
this review. For instance, loss-of-function mutations in the aldoste-
rone synthase gene (CYP11B2) can lead to reduced aldosterone levels,
hypovolaemia, hypotension and shock [92–94]. Other examples
include familiar hyperaldosteronism type II, congenital adrenal
hyperplasia, mutations in the PPARG gene and hypertension and
bradydactyly [6,79,91]. Some of these syndromes can be caused by
mutations in several genes, some have not yet been localised to a
gene, or have been localised but still lack understanding of the
mechanisms that lead to hypertension.
One of the major discoveries in recent years was the description of
the WNK (with no K [lysine]) kinases and their role in the
pathogenesis of hypertension. The WNK1 and WNK4 serine-threo-
nine kinases regulate the sodium, chloride and potassium transport
mechanisms in the distal nephron [95–97]. WNK1 and WNK4
mutations have been identiﬁed to cause Gordon syndrome (pseudo-
hypoaldosteronism type 2) [98]. It has then be demonstrated that
variants of theWNK1 gene not only cause this severe Mendelian form
of hypertension but that more subtle variants are also associated with
blood pressure variation in a severely hypertensive [99] and in the
general population [100].
This ﬁnding supports the hypothesis that common variants
underlying the Mendelian forms of hypertension could affect blood
pressure variation in the general population and thereby be
involved in the pathogenesis of hypertension. In 2008, Tobin etal. [101] demonstrated that variants of the KCNJ1 gene causing
Bartter syndrome type 2 (Table 1) were strongly associated with
mean 24-hour systolic or diastolic blood pressure. Associations
were also found for CASR, NR3C2, SCNN1B and SCMM1G (Table 1).
Although this study was a milestone in understanding the role of
common variants in genes causing monogenic hypertension for
regulation of blood pressure in the general population it indeed
dealt with common variants (minor allele frequency >1%). The
study by Tobin et al. [101] is a candidate gene study and awaits
replication in independent cohorts. In the same year, however, Ji et
al. [102] opened a completely new avenue of research by also
testing three genes which underlie Mendelian forms of hyperten-
sion (SLC12A3, SLC12A1 and KCNJ1) in a general population cohort
derived from the Framingham Heart Study. In contrast to the work
by Tobin et al. [101], these authors have screened all coding exons
and ﬂanking introns for rare DNA sequence variants and found a
total of 138 different coding sequence variants in 2492 subjects
[102]. These mutations were associated with reduced prevalence of
hypertension. Quantitatively, mean systolic blood pressure was
5.7 mmHg, 6.4 mmHg and 9.0 mmHg lower at the age of 40, 50 and
60 years, respectively, in carriers of the mutation compared to non-
carriers. Thereby, these rare mutations in just three genes
contributed equally or more to blood pressure variation in the
general population than the common variants identiﬁed by the
recent GWAS [89,90]. Direct sequencing may be a promising tool to
identify rare (i.e. minor allele frequency <1%) mutations that are
not usually covered in GWAS. The above example demonstrates
that such rare variants in genes whose pathophysiological role in
the regulation of blood pressure is beyond any doubt can help to
explain blood pressure variability in the population.
10. Summary and open questions
As a result of enormous effort a number of plausible and validated
genetic variants that are associated with blood pressure and/or
hypertension have recently been found. It emerged that these variants
are either common and in turn contribute little to blood pressure
variation [89,90] or are rare and have a relatively strong effect [102].
The future development of this area is difﬁcult to predict but will most
likely see a combination of GWAS and sequencing studies in large
cohorts.
The past ten years have also demonstrated that accurate pheno-
typing is one of the keys to discover genetic determinants of disease.
This may be less of an issue in relatively clearly deﬁned diseases
such as type 1 diabetes or Crohn's disease but is a major problem in
hypertension where there is a somewhat arbitrary cut-off for
deﬁnition of disease, marked sexual dimorphism, marked age effect,
and a substantial inﬂuence of environmental factors. Unsurprisingly
genetics of hypertension has been less of a success story compared to
other common diseases, but the high impact of hypertension on
cardiovascular morbidity and mortality more than justiﬁes further
efforts. The role of intermediate phenotypes including endothelial
function and vascular stiffness but also associated phenotypes such as
body weight and renal function [83] in gene discovery remains to be
elucidated. It is also not clear whether an approach in the general
population targeted towards blood pressure variation (quantitative
trait) or an approach in selected extremes of cases and controls
(quantitative trait) is superior. Most likely both approaches have their
own merits.
Finally, we have witnessed substantial progress in both human
genetics and animal models of hypertension, but have seen few truly
translational studies. It appears that both approaches have been
developed in parallel with little focus on informing each other. This
will almost certainly change in the next few years, but probably not
necessarily in the direction “animal to man” but more likely in the
direction “man to animal”. The highly sophisticated tools that are now
Table 1
Mendelian forms of hypotension and hypertension.
Disorder Gene/locus Age of onset Disease mechanism Features References
Syndromes associated with low blood pressure
Gitelman syndrome SLC12A3 Adolescence or
adulthood
Loss-of-function mutations in the gene
encoding the thiazide-sensitive Na–Cl
cotransporter of the distal collecting duct
causes salt wasting and activation of the
renin–angiotensin–aldosterone system.
Thereby maintenance of serum sodium
but loss of potassium and H+ by
augmentation of the epithelial sodium
channel
Hypokalaemia with metabolic alkalosis.
Low serum Mg2+ and low urinary Ca2+
levels
[103,104]
16q3
Bartter syndrome Often associated with preterm delivery.
In contrast to Gitelman syndrome,
normal or only mildly reduced serum
Mg2+ and increased urinary Ca2+ levels
Type 1 SLC12A Neonatal Loss of function of the apical Na–K–2Cl
cotransporter
[105]
15q21
Type 2 KCNJ1 Neonatal Mutations of the ATP-sensitive K+
channel ROMK affect K+ recycling and
thereby inhibit Na+ reabsorption in the
thick ascending limb of Henle
[106]
11q24
Type 3 CLCNKB School age Loss-of-function mutations in the Cl−
channel CLCNKB in the thick ascending
limb of Henle. Some of these mutations
have arisen from unequal crossing over
between CLCNKB and the nearby related
gene CLCNKA
[107]
1p36
Type 4 BSND Neonatal BSND encodes Barttin which functions as
a beta-subunit for CLCNKA and CLCNKB
chloride channels
Associated with sensorineural deafness.
inhibition of NaCl reabsorption in type IV
Bartter syndrome is not restricted to the
thick ascending limb of Henle
[108]
1p32
Type 5 CASR Adulthood Mutations activating the calcium-sensing
receptor CaSR which then inhibits
sodium transport in the thick ascending
limb of the loop of Henle
Associated with autosomal dominant
hypocalcaemia (ADH)
[109]
3q13
Autosomal dominant
pseudohypoaldosteronism type I
NR3C2 Neonatal Loos/of/function mutations in the
mineralocorticoid receptor impairing
maximum salt absorption. The reduced
activity of the endothelial sodium
channel affects H+ and K+ excretion
Salt wasting with hypotension despite
markedly elevated aldosterone levels;
hyperkalemia and metabolic acidosis.
Often asymptomatic in adulthood on
usual western (high salt) diet
[110,111]
4q31
Recessive pseudohypoaldosteronism
type I
SCNN1A Neonatal Loss-of-function mutations in any of the
three different subunits of the epithelial
sodium channel
Salt wasting and hypotension with
hyperkalemia and metabolic acidosis,
despite high levels of aldosterone.
Require high dose salt supplementation
[112]
16p12
SCNN1B
12p13
SCNN1G
16p12
Syndromes associated with high blood pressure
Glucorticoid-remediable
aldosteronism
CYP11B2 and
CYP11B1
Second or
third decade
Gene duplication due to unequal crossing
over between the aldosterone synthase
(CYP11B2) and steroid 11β-hydroxylase
(CYP11B1) genes. The resulting chimaeric
gene encodes a protein under the
regulation of ACTH with aldosterone
synthase activity
Normal or elevated aldosterone levels
despite suppressed plasma renin activity.
Hypokalaemia and metabolic alkalosis
are variable associated ﬁndings.
Exogenous glucocorticoids completely
suppress aldosterone secretion
[113–116]
8q21
Apparent mineralocorticoid excess HSD11B2 Childhood Absence of the enzyme 11β-
hydroxysteroid dehydrogenase allows
cortisol to activate MR, resulting in
hypertension mediated by increased
epithelial sodium channel activity
Hypokalaemia and metabolic alkalosis
accompanied by suppressed plasma
renin activity and the virtual absence of
circulating aldosterone
[117,118]
16q22
Hypertension exacerbated
in pregnancy
NR3C2 Before second
decade
Missense mutation, S810L, in the
mineralocorticoid receptor causing
normal activation by aldosterone but also
activation by ligands that are normally
silent or antagonistic (e.g. progesterone)
Exacerbation during pregnancy due to
the increased progesterone levels
[119]
4q31
Liddle syndrome SCNN1B Adolescence Mutations in either the β or the γ subunit
of the epithelial sodium channel delete
their cytoplasmic C termini and result in
increased channel activity
Associated with hypokalaemic alkalosis,
suppressed plasma renin activity, and
low plasma aldosterone levels
[120–122]
12p13
SCNN1G
16p12
Pseudohyperaldosteronism type II
(Gordon syndrome)
WNK1, 12p13 Second or third
decade
WNK kinases are expressed in the distal
nephron and are involved in the control
of renal electrolyte homeostasis
Hyperkalaemia and low aldosterone
levels. Sensitive to treatment with
thiazide diuretics
[95,98]
WNK4, 17q21
1305C. Delles et al. / Biochimica et Biophysica Acta 1802 (2010) 1299–1308
1306 C. Delles et al. / Biochimica et Biophysica Acta 1802 (2010) 1299–1308available for human genomic studies have led to the identiﬁcation of
numerous causative genes and genetic loci that require detailed
studies of function in experimental models.
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